Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23241883 | 0.86 | HSD17B10 (0.34) | HSD17B10SYKKCNH2HCRTR1HCRTR2 | |
| SCHEMBL536855 | 0.82 | SYK (0.36) | HSD17B10CCR1SYKHCRTR1HCRTR2 | |
| SCHEMBL536702 | 0.82 | CCR1 (0.35) | CCR1KCNH2HCRTR1HCRTR2 | |
| SCHEMBL2455139 | 0.80 | HSD17B10 (0.45) | HSD17B10SYK | |
| SCHEMBL536703 | 0.78 | HCRTR1 (0.41) | CCR1HCRTR1HCRTR2 | |
| SCHEMBL536792 | 0.77 | HSD17B10 (0.33) | HSD17B10SYKKCNH2 | |
| SCHEMBL15650448 | 0.76 | HSD17B10 (0.39) | HSD17B10SYK | |
| SCHEMBL30354979 | 0.76 | HSD17B10 (0.39) | HSD17B10SYK | |
| SCHEMBL29100955 | 0.74 | MBOAT4 (0.46) | CCR1SYKKCNH2 | |
| SCHEMBL1020165 | 0.73 | P2RX7 (0.43) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | LIGAND UK DEVELOPMENT LIMITED (GB) | 2023-03-30 | — | — | US | disclosed |
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
| US-20210115054-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2021-04-22 | — | — | US | disclosed |
| US-10875868-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2020-12-29 | — | — | US | disclosed |
| US-20200172547-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10538526-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2020-01-21 | — | — | US | disclosed |
| US-20190031668-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| US-10106547-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20170342081-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2017-11-30 | — | — | US | disclosed |
| US-9765080-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20170088552-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2017-03-30 | — | — | US | disclosed |
| US-9376443-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2016-06-28 | — | — | US | disclosed |
| US-20150291602-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-8987279-B2 | Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2013-09-19 | — | — | US | disclosed |
| US-8450328-B2 | Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| EP-2321321-B1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2011-07-14 | — | — | US | disclosed |
| EP-2321321-A1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | Vernalis (R&D) Limited (GB) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009156737-A1 | TRIAZOLO [4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106547-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | HSD17B10 4614/4885CCR1 1357/4885SYK 3399/4885 |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HSD17B10 4614/4885CCR1 1357/4885SYK 3399/4885 |
| US-20170342081-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HSD17B10 4614/4885CCR1 1357/4885SYK 3399/4885 |
| US-20190031668-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HSD17B10 4614/4885CCR1 1357/4885SYK 3399/4885 |
| US-20170088552-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HSD17B10 4652/4885CCR1 1283/4885SYK 3413/4885 |
| US-10875868-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | HSD17B10 4652/4885CCR1 1283/4885SYK 3413/4885 |
| US-20210115054-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HSD17B10 4614/4885CCR1 1357/4885SYK 3399/4885 |
| US-10538526-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | HSD17B10 4614/4885CCR1 1357/4885SYK 3399/4885 |
| US-20150291602-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HSD17B10 4652/4885CCR1 1283/4885SYK 3413/4885 |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HSD17B10 4614/4885CCR1 1357/4885SYK 3399/4885 |
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | HSD17B10 4614/4885CCR1 1357/4885SYK 3399/4885 |
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HSD17B10 4614/4885CCR1 1357/4885SYK 3399/4885 |
| US-20200172547-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | HSD17B10 4652/4885CCR1 1283/4885SYK 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.